[1]

Includes external research expenses, clinical studies, manufacturing including manufacturing and non-recurring engineering costs, professional and consulting, regulatory, and trade shows for 2026.

[2]

Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, marketing expenses for 2026 and other office expenses.

[3]

Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.

Major Customers

For the three and six months ended June 30, 2026, four cancer center customers for the Company's RenovoCath device, (referred to for these purposes as Customers A, B, C, and D) each accounted for more than 10% of the Company's total revenue. For the three months ended June 30, 2026, Customers A, B and C accounted for 20.0%, 16.8% and 15.2%, respectively. For the six months ended June 30, 2026, Customers A, B, C, and D accounted for 15.3%, 20.8%, 11.1%, and 10.4%, respectively.

For the three and six months ended June 30, 2025, five cancer center customers for the Company's RenovoCath device (referred to for these purposes as Customers A, B, C, D and E) each accounted for more than 10% of the Company's total revenue. For the three months ended June 30, 2025, Customers A, B, C, D, and E accounted for 28.3%, 14.1%, 16.2%, 11.3%, and 10.1%, respectively. For the six months ended June 30, 2025, Customers A, B, C, and E accounted for 23.5%, 20.7%, 19.3%, and 15.2%, respectively.